Ann: Share Purchase Plan, page-36

If you don't understand what that means then I can't help you. It's not that hard to understand, but it's also beside the entire point. I can't help you any more random professor dude. You've married this stock or something.


RE satipharm in the US. I hope that it is successful and that all CANN investors are rewarded for their faith - they deserve to be rewarded for going on this tough journey. But realistically the chances of low-dose CBD doing well there is very low. The US market is saturated with high quality bud. Almost every strain you could imagine. Then you have resin, rosin, and all these other speciality products that we can't even fathom over here. Satipharm in the US would not be a viable prospect in my opinion. In fact, I think it will be a flop here as well.